Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction
The benchmark registry
Gregg W. Stone, MD, FACC*,*,
E. Magnus Ohman, MD, FACC
,
Michael F. Miller, PhD
,
Debra L. Joseph, BSN
,
Jan T. Christenson, MD, FECTS||,
Marc Cohen, MD, FACC¶,
Philip M. Urban, MD, FACC#,
Ramachandra C. Reddy, MD, FACC**,
Robert J. Freedman, MD, FACC
,
Karen L. Staman, MS
and
James J. Ferguson, III, MD, FACC
* Cardiovascular Research Foundation and Lenox Hill Hospital, New York, New York, USA
University of North Carolina, Chapel Hill, North Carolina, USA
M. F. Miller Statistical Services, Langhorne, Pennsylvania, USA
Datascope Corp., Fairfield, New Jersey, USA
|| University of Geneva Hospital, Geneva, Switzerland
¶ Hahnemann University Hospital, Philadelphia, Pennsylvania, USA
# Hôpital de la Tour, Geneva, Switzerland
** State University of New York Health Science Center, Brooklyn, New York, USA

St. Francis Cabrini Medical Center, Alexandria, Louisiana, USA

Duke Clinical Research Institute, Durham, North Carolina, USA

Texas Heart Institute, Houston, Texas, USA

View larger version (23K):
[in a new window]
|
Figure 1 In-hospital mortality of 5,495 patients with acute myocardial infarction (AMI) requiring intra-aortic balloon pump counterpulsation, stratified by principal usage indication. PCI = percutaneous coronary intervention.
|
|

View larger version (16K):
[in a new window]
|
Figure 2 In-hospital mortality stratified by the performance of angiography and percutaneous or surgical coronary revascularization.
|
|
Copyright © 2003 by the American College of Cardiology Foundation.